RxDoctor Payments Data

Dhruti Patel, MD

Urology · Saint Louis, MONPI 1407172877

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.0%), travel and lodging and other — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 28.9% of the total. Reporting peaked in 2021 at $3,207 and has fallen 95.3% since, to $152 in 2025.

$12,120in general payments, 2019–2025

Across 131 payments — averaging $92.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Boston Scientific$2K
  • Teleflex LLC$2K
  • EDAP Technomed Inc$2K
  • Endo Pharmaceuticals Inc.$273
  • AbbVie$266
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$4,37236%
  • Food & beverage$5,09442%
  • Education$1301%
  • Gifts$230%
  • Other$2,50021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,120 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$37,113
Medicare patients
123
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron55$32,871
GemtesaVibegron36$29,510
Estradiol96$4,954
Tamsulosin Hcl135$2,913
Trospium Chloride17$1,680
Potassium Citrate ErPotassium Citrate16$1,474
Finasteride58$481
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$175
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$131
Cefdinir14$130
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$93
Cephalexin28$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$161$32,87155 claims
Sumitomo Pharma America, Inc.Gemtesa$88$29,51036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.

Other urology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →